Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
GB Sciences, Inc. (GBLX)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
3550 West Teco Avenue 89118
Las Vegas, NV, US
Las Vegas, NV, US
CEO
Andrea Small-Howard
Website
gbsciences.com
IPO
2008-05-12
CIK 1165320 ISIN US3615441090
Description
Operating across North America and Europe, GB Sciences, Inc. is dedicated to the research and development of plant-based pharmaceuticals. The company specializes in crafting cannabinoid-inspired medications and complex therapeutic formulations intended for the prescription drug market. Its extensive intellectual property portfolio addresses a variety of medical conditions, with programs currently in pre-clinical animal stages. These include initiatives for Parkinson's disease, neuropathic and chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular ailments. Formed in 2001 and headquartered in Las Vegas, Nevada, the company was formerly known as Growblox Sciences, Inc. before rebranding in October 2016.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
43.5K
Beta
9.86
Float Shares
401.85M
Free Float %
98.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -40.00% | +0.00% | -97.69% | -99.51% | -99.90% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-1,735.95
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+64.4% ★ Q4'24: +60.0% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%— Q4'24: -364.9% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%— Q4'24: -68.5% (vs Q4'23)
-
ROIC Biotechnology: -16.1%— Q4'24: +6.8% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+10.9% Q4'24: +1.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.24× Q4'24: -7.50× (vs Q4'23)
Valuation Multiples
From
To
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-736.9K
OE per share TTM
0.00
Owner's Yield
-603.42%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
472.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
4
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Justin B. Borus | 4.11M | 3.70% | 4.11M | — | 4.11M | — | HC, IN | United States | 2017-05-31 | ↗ |
| 2 | Lazarus Management Company LLC | 4.11M | 3.70% | 4.11M | — | 4.11M | — | IA | Colorado | 2017-05-31 | ↗ |
| 3 | Lazarus Investment Partners LLLP | 2.11M | 1.90% | 2.11M | — | 2.11M | — | PN | Delaware | 2017-05-31 | ↗ |
| 4 | Lazarus Israel Opportunities Fund LLLP | 2.00M | 1.80% | 2.00M | — | 2.00M | — | PN | Delaware | 2017-05-31 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
7
Sells
0
Shares acquired
100.0K
Shares disposed
—
Cash buys
7.00
Cash sales
—
Net activity
+99,964
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018-07-11 | POSS JOHN C | Director / Officer | P-Purchase | A | Common Stock | 3,615 | 0.41 | 1.5K | 231,049 | — | ↗ |
| 2017-11-27 | POSS JOHN C | Director / Officer | — | D | Options | 937,500 | 0.24 | 225.0K | 0 | — | ↗ |
| 2017-08-04 | Ellins Craig | — | S-Sale | D | Common Stock | 30,000 | 0.26 | 7.7K | 5,711,000 | — | ↗ |
| 2017-08-03 | Ellins Craig | — | S-Sale | D | Common Stock | 20,000 | 0.26 | 5.1K | 5,741,000 | — | ↗ |
| 2017-08-02 | Ellins Craig | — | S-Sale | D | Common Stock | 50,000 | 0.26 | 12.8K | 5,761,000 | — | ↗ |
| 2017-04-24 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 7,214 | 0.30 | 2.2K | 2,147,278 | — | ↗ |
| 2017-04-18 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 16,068 | 0.29 | 4.7K | 2,154,492 | — | ↗ |
| 2017-04-17 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 16,068 | 0.31 | 5.0K | 2,170,560 | — | ↗ |
| 2017-04-11 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 32,100 | 0.29 | 9.4K | 2,186,628 | — | ↗ |
| 2017-04-10 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 32,100 | 0.31 | 9.9K | 2,218,728 | — | ↗ |
| 2017-04-07 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 10,000 | 0.30 | 3.0K | 2,250,828 | — | ↗ |
| 2017-04-06 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 8,742 | 0.31 | 2.7K | 2,260,828 | — | ↗ |
| 2017-04-05 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 34,633 | 0.32 | 11.0K | 2,269,570 | — | ↗ |
| 2017-04-04 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 20,000 | 0.33 | 6.7K | 2,304,203 | — | ↗ |
| 2017-04-03 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 27,544 | 0.34 | 9.3K | 2,324,203 | — | ↗ |
| 2017-03-30 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 15,313 | 0.32 | 4.9K | 2,351,747 | — | ↗ |
| 2017-03-29 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 21,500 | 0.33 | 7.1K | 2,367,060 | — | ↗ |
| 2017-03-28 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 12,200 | 0.31 | 3.8K | 2,388,560 | — | ↗ |
| 2017-03-27 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 10,800 | 0.30 | 3.3K | 2,400,760 | — | ↗ |
| 2017-03-21 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 16,630 | 0.31 | 5.2K | 2,411,560 | — | ↗ |
| 2017-03-20 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 11,810 | 0.32 | 3.8K | 2,428,190 | — | ↗ |
| 2017-03-16 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 50,000 | 0.33 | 16.5K | 2,440,000 | — | ↗ |
| 2017-03-15 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 50,000 | 0.32 | 16.2K | 2,490,000 | — | ↗ |
| 2017-03-14 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 25,000 | 0.33 | 8.2K | 2,540,000 | — | ↗ |
| 2017-03-13 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 30,000 | 0.33 | 9.8K | 2,565,000 | — | ↗ |
| 2017-03-10 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 25,000 | 0.33 | 8.2K | 2,595,000 | — | ↗ |
| 2017-03-09 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 100,000 | 0.33 | 32.9K | 2,620,000 | — | ↗ |
| 2017-03-08 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 65,000 | 0.35 | 22.6K | 2,720,000 | — | ↗ |
| 2017-03-07 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 35,000 | 0.36 | 12.5K | 2,785,000 | — | ↗ |
| 2017-03-03 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 25,793 | 0.35 | 9.0K | 2,820,000 | — | ↗ |
| 2017-03-02 | Ellins Craig | Director / Officer | S-Sale | D | Common Stock | 74,207 | 0.35 | 25.8K | 2,845,793 | — | ↗ |
| 2016-10-06 | Lazarus Management Co LLC | 10% Owner | S-Sale | D | Common Stock | 600,000 | 0.30 | 182.9K | 3,906,479 | — | ↗ |
| 2016-10-05 | Lazarus Management Co LLC | 10% Owner | S-Sale | D | Common Stock | 122,500 | 0.33 | 40.6K | 4,506,479 | — | ↗ |
| 2016-10-04 | Lazarus Management Co LLC | 10% Owner | S-Sale | D | Common Stock | 62,500 | 0.35 | 21.7K | 4,628,979 | — | ↗ |
| 2016-06-01 | POSS JOHN C | Director / Officer | — | D | Options | 1,400,000 | 0.30 | 420.0K | 0 | — | ↗ |
| 2015-08-10 | POSS JOHN C | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 125,000 | — | ↗ |
| 2015-04-27 | Lazarus Management Co LLC | 10% Owner | S-Sale | D | Warrant (right to buy) | 1,000,000 | 2.00 | 2.00M | 0 | — | ↗ |
| 2015-03-31 | Lazarus Management Co LLC | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-10-08 | Lazarus Management Co LLC | 10% Owner | P-Purchase | A | Common Stock | 25,000 | 0.66 | 16.6K | 1,420,647 | — | ↗ |
| 2014-10-07 | Lazarus Management Co LLC | 10% Owner | P-Purchase | A | Common Stock | 35,100 | 0.69 | 24.3K | 1,395,647 | — | ↗ |
| 2014-10-06 | Lazarus Management Co LLC | 10% Owner | P-Purchase | A | Common Stock | 17,600 | 0.75 | 13.1K | 1,360,547 | — | ↗ |
| 2014-10-03 | Lazarus Management Co LLC | 10% Owner | L-Small | A | Common Stock | 600 | 0.83 | 496.98 | 1,342,947 | — | ↗ |
| 2014-10-02 | Lazarus Management Co LLC | 10% Owner | P-Purchase | A | Common Stock | 12,605 | 0.80 | 10.1K | 1,342,347 | — | ↗ |
| 2014-10-01 | Lazarus Management Co LLC | 10% Owner | P-Purchase | A | Common Stock | 10,900 | 0.82 | 9.0K | 1,329,742 | — | ↗ |
| 2014-09-30 | Lazarus Management Co LLC | 10% Owner | P-Purchase | A | Common Stock | 16,100 | 0.90 | 14.5K | 1,318,842 | — | ↗ |
| 2014-09-29 | Lazarus Management Co LLC | 10% Owner | P-Purchase | A | Common Stock | 21,400 | 0.90 | 19.3K | 1,302,742 | — | ↗ |
| 2014-09-26 | Lazarus Management Co LLC | 10% Owner | P-Purchase | A | Common Stock | 12,600 | 0.91 | 11.4K | 1,281,342 | — | ↗ |
| 2014-09-25 | Lazarus Management Co LLC | 10% Owner | P-Purchase | A | Common Stock | 30,000 | 0.90 | 26.9K | 1,268,742 | — | ↗ |
| 2014-09-24 | Lazarus Management Co LLC | 10% Owner | L-Small | A | Common Stock | 2,300 | 0.86 | 2.0K | 1,238,742 | — | ↗ |
| 2014-09-23 | Lazarus Management Co LLC | 10% Owner | L-Small | A | Common Stock | 3,200 | 0.86 | 2.8K | 1,236,442 | — | ↗ |
| 2014-09-22 | Lazarus Management Co LLC | 10% Owner | L-Small | A | Common Stock | 2,600 | 0.89 | 2.3K | 1,233,242 | — | ↗ |
| 2014-09-17 | Lazarus Management Co LLC | 10% Owner | P-Purchase | A | Common Stock | 5,600 | 0.73 | 4.1K | 1,230,642 | — | ↗ |
| 2014-09-17 | Lazarus Israel Opportunities Fund LLLP | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-09-16 | Lazarus Management Co LLC | 10% Owner | P-Purchase | A | Common Stock | 20,000 | 0.76 | 15.2K | 1,225,042 | — | ↗ |
| 2014-09-15 | Lazarus Management Co LLC | 10% Owner | P-Purchase | A | Common Stock | 22,040 | 0.77 | 17.0K | 1,205,042 | — | ↗ |
| 2014-09-09 | Lazarus Management Co LLC | 10% Owner | L-Small | A | Common Stock | 1,000 | 0.96 | 960.00 | 1,183,002 | — | ↗ |
| 2014-09-03 | Lazarus Management Co LLC | 10% Owner | L-Small | A | Common Stock | 1,500 | 1.04 | 1.6K | 1,182,002 | — | ↗ |
| 2014-08-29 | Lazarus Management Co LLC | 10% Owner | L-Small | A | Common Stock | 500 | 1.08 | 540.00 | 1,180,502 | — | ↗ |
| 2014-08-27 | Lazarus Israel Opportunities Fund LLLP | 10% Owner | P-Purchase | A | Common Stock | 14,425 | 1.04 | 15.0K | 1,180,002 | — | ↗ |
| 2014-08-26 | Lazarus Israel Opportunities Fund LLLP | 10% Owner | P-Purchase | A | Common Stock | 32,200 | 1.06 | 34.1K | 1,165,577 | — | ↗ |
| 2014-08-25 | Lazarus Israel Opportunities Fund LLLP | 10% Owner | L-Small | A | Common Stock | 6,500 | 1.13 | 7.3K | 1,133,377 | — | ↗ |
| 2014-08-01 | Lazarus Israel Opportunities Fund LLLP | 10% Owner | P-Purchase | A | Common Stock | 10,000 | 1.23 | 12.3K | 1,126,877 | — | ↗ |
| 2014-07-31 | Lazarus Israel Opportunities Fund LLLP | 10% Owner | P-Purchase | A | Common Stock | 29,800 | 1.24 | 37.0K | 1,116,877 | — | ↗ |
| 2014-07-30 | Lazarus Israel Opportunities Fund LLLP | 10% Owner | P-Purchase | A | Common Stock | 13,600 | 1.24 | 16.9K | 1,087,077 | — | ↗ |
| 2014-07-29 | Lazarus Israel Opportunities Fund LLLP | 10% Owner | P-Purchase | A | Common Stock | 54,700 | 1.25 | 68.2K | 1,073,477 | — | ↗ |
| 2014-07-28 | Lazarus Israel Opportunities Fund LLLP | 10% Owner | P-Purchase | A | Common Stock | 18,777 | 1.21 | 22.7K | 1,018,777 | — | ↗ |
| 2014-07-02 | LAZARUS INVESTMENT PARTNERS LLLP | 10% Owner | P-Purchase | A | Common Stock | 20,000 | 1.20 | 24.0K | 3,269,632 | — | ↗ |
| 2014-07-01 | LAZARUS INVESTMENT PARTNERS LLLP | 10% Owner | P-Purchase | A | Common Stock | 50,000 | 1.21 | 60.5K | 3,249,632 | — | ↗ |
| 2014-06-30 | LAZARUS INVESTMENT PARTNERS LLLP | 10% Owner | P-Purchase | A | Common Stock | 199,632 | 1.19 | 237.6K | 3,199,632 | — | ↗ |
| 2014-06-02 | Lazarus Management Co LLC | 10% Owner | P-Purchase | A | Common Stock | 1,000,000 | 0.50 | 500.0K | 4,000,000 | — | ↗ |
| 2014-06-02 | Lazarus Israel Opportunities Fund LLLP | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,000,000 | — | ↗ |
| 2014-05-29 | LAZARUS INVESTMENT PARTNERS LLLP | 10% Owner | — | D | Warrant | 3,000,000 | 2.00 | 6.00M | 0 | — | ↗ |
| 2014-03-13 | Ellins Craig | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 3,127,692 | — | ↗ |
Executive team
Top executives
Shares Outstanding
407.07M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2016 | Craig Ellins, CIO and Chairman | 137.2K | — | — | 860.0K | — | — | 997.2K | 86.24% | ↗ |
| 2 | 2016 | John Poss, CEO, COO and Director | 55.1K | — | — | 179.6K | — | — | 234.6K | 76.54% | ↗ |
| 3 | 2016 | Dr. Andrea Small-Howard, CSO and Director | 63.0K | — | — | — | — | — | 63.0K | 0.00% | ↗ |
| 4 | 2015 | Dr. Andrea Small-Howard, CSO and Director | 62.7K | — | 756.0K | 84.4K | — | — | 903.1K | 93.06% | ↗ |
| 5 | 2015 | Craig Ellins, CIO and Chairman | 168.6K | — | — | — | — | — | 168.6K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andrea Small-Howard | CEO, Interim CFO, Chairman of Scientific Advisory Board, CSO, President & Chairman of the Board | 144.0K | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GBLX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
